Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

107 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823

Allergic Conjunctivitis

COMPLETED PHASE2

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

NCT00586664

Allergic Conjunctivitis

COMPLETED PHASE3

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

NCT00586625

Allergic Conjunctivitis

COMPLETED PHASE3

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

NCT00241319

Allergic Conjunctivitis

COMPLETED PHASE3

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543

Allergic Conjunctivitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Conjunctivitis, Allergic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bepreve

Bepotastine Besilate Ophthalmic Solution 1.5%

Group Type EXPERIMENTAL

Bepreve

Intervention Type DRUG

sterile ophthalmic solution

Placebo

sterile ophthalmic solution

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

sterile ophthalmic solution

Bepotastine Besilate

sterile ophthalmic solution 1.0%

Group Type EXPERIMENTAL

Bepotastine Besilate

Intervention Type DRUG

sterile ophthalmic solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bepreve

sterile ophthalmic solution

Intervention Type DRUG

Placebo

sterile ophthalmic solution

Intervention Type DRUG

Bepotastine Besilate

sterile ophthalmic solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 10 years of age \& either sex, any race
* Willing and able to follow all instructions and attend all study visits
* Positive history of ocular allergies